MENU

 

A Novel Method for Designing Vaccines Against Constantly Mutating Pathogens

 

Eduardo A. Padlan

Marine Science Institute, College of Science
University of the Philippines, Diliman, Quezon City, Philippines

*corresponding author: This email address is being protected from spambots. You need JavaScript enabled to view it./ This email address is being protected from spambots. You need JavaScript enabled to view it.

 

ABSTRACT


A method is described that could be used to design molecules suitable as vaccines for immunization, or for the generation of therapeutic antibodies against constantly mutating pathogens. The method consists of (1) locating the putative immunodominant epitopes of a protein antigen, and identifying the residues that contribute to the high antigenicity of the epitopes and (2) replacing those residues judiciously to reduce the antigenicity of the immunodominant epitopes, while preserving structure. The antibody response to the modified antigen would then be expected to be directed against more parts of the molecule, and not mainly against the formerly immunodominant epitopes. The method is also useful in the design of molecules suitable for immunization against pathogens that had been intentionally mutated so as to render those pathogens able to infect previously immune individuals.


INTRODUCTION


Many pathogens are able to evade the immune system by constantly mutating their surface molecules. In so doing, the antibodies, which had been generated against previous strains of the pathogens, are no longer totally protective. In many instances, the pathogens are able to make the evasive move by mutating a few amino acids in a surface molecule that may contain several hundred residues.
Among the pathogens that are constantly mutating to achieve immune evasion are the influenza virus, the cold virus, and the virus that causes AIDS. These and other viruses and other pathogens have molecules on their surface, some of which are used to recognize and bind to the cells that the pathogens infect. Those surface molecules are the targets of the antibodies that our immune system produces to combat the pathogens. The external regions of those molecules can be used as vaccines. But a vaccine that utilizes a surface molecule, or part thereof, of a particular pathogen will be effective against mainly that pathogen, and may not offer protection against new or other strains of the organism.

 

[DOWNLOAD FULL TEXT HERE]

 

REFERENCES

BERMAN HM, WESTBROOK J, FENG Z, GILLILAND G, BHAT TN, WEISSIG H, SHINDYALOV IN, BOURNE PE. 2000. The Protein Data Bank. Nucleic Acids Research 28: 235-242.

CHEN J, LEE KH, STEINHAUER DA, STEVENS DJ, SKEHEL JJ, WILEY DC. 1998. Structure of the hemagglutinin precursor cleavage site, a determinant of influenza pathogenicity and the origin of the labile conformation. Cell 95: 409-417. 

CONNOLLY ML. 1983. Solvent-accessible surfaces of proteins and nucleic acids. Science 221: 709-713.

DAVID MP, ASPRER JJ, IBANA JS, CONCEPCION GP, PADLAN EA. 2007. A study of the structural correlates of affinity maturation: Antibody affinity as a function of chemical interactions, structural plasticity and stability. Molecular Immunology 44: 1342-51.

DE GENST E, ARESKOUG D, DECANNIERE K, MUYLDERMANS S, ANDERSSON K. 2002. Kinetic and affinity predictions of a protein-protein interaction using multivariate experimental design. Journal of Biological Chemistry 277: 29897-907.

FAZEKAS DE ST. GROTH S. 1977. Antigenic, adaptive and adsorptive variants of the influenza haemagglutinin. In: Topics in Infectious Diseases 3 (eds RG Laver, H Bachmayer & R Weil) pp. 25-48. Springer-Verlag, Vienna.

GRANTHAM R. 1974. Amino acid difference formula to help explain protein evolution. Science 185: 862-864.

GULATI U, HWANG CC, VENKATRAMANI L, GULATI S, STRAY SJ, LEE JT, LAVER WG, BOCHKAREV A, ZLOTNICK A, AIR GM. 2002. Antibody epitopes on the neuraminidase of a recent H3N2 influenza virus (A/Memphis/31/98). Journal of Virology 76: 12274-80.

HENNECKE J, CARFI A and WILEY DC. 2000. Structure of a covalently stabilized complex of a human alphabeta T-cell receptor, influenza HA peptide and MHC class II molecule, HLA-DR1. EMBO Journal 19: 5611-24.

HOPP TP and WOODS KR. 1981. Prediction of Protein Antigenic Determinants from Amino Acid Sequences. Proceedings of the National Academy of Science USA 78: 3824-28.

HUTCHINSON EG, THORNTON JM. 1994. A revised set of potentials for beta-turn formation in proteins. Protein Science 3: 2207-16.

KABSCH W, SANDER C. 1983. Dictionary of protein secondary structure: pattern recognition of hydrogenbonded and geometrical features. Biopolymers 22: 2577-637.

LEE MS, CHEN JS. 2004. Predicting antigenic variants of influenza A/H3N2 viruses. Emerging Infectious Diseases 10: 1385-90.

LINDING R, RUSSELL RB, NEDUVA V, GIBSON TJ. 2003. GlobPlot: exploring protein sequences for globularity and disorder. Nucleic Acids Research 31: 3701-08.

MACKEN C, LU H, GOODMAN J, BOYKIN L. 2001. The value of a database in surveillance and vaccine selection. In: Options for the Control of Influenza IV (eds ADME Osterhaus, N Cox & AW Hampson) p. 103-106. Elsevier Science, Amsterdam.

MARTINET W, DEROO T, SAELENS X, BEIRNAERT E, VANLANDSCHOOT P, CONTRERAS R, FIERS W, MIN JOU W. 1998. Evaluation of recombinant A/Victoria/3/75 (H3N2) influenza neuraminidase mutants as potential broad-spectrum subunit vaccines against influenza. Archives of Virology 143: 2011-19.

NOVOTNY J. 1991. Protein antigenicity: a thermodynamic approach. Molecular Immunology 28: 201-227.

PACE CN, SCHOLTZ JM. 1998. A helix propensity scale based on experimental studies of peptides and proteins. Biophysical Journal 75: 422-427.

PADLAN EA. 1985. Quantitation of the immunogenic potential of protein antigens. Molecular Immunology 22: 1243-54.

PADLAN EA. 1990. On the Nature of Antibody Combining Sites: Unusual Structural Features That May Confer on These Sites an Enhanced Capacity for Binding Ligands. PROTEINS: Structure Function & Genetics 7: 112-124.

PADLAN EA. 1996. X-ray Crystallography of Antibodies. Advances in Protein Chemistry 49: 57-133.

RAMMENSEE H-G, BACHMANN J, EMMERICH NN, BACHOR OA, STEVANOVIC S. 1999. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 50: 213-219.

SANDBERG M, ERIKSSON L, JONSSON J, SJOSTROM M, WOLD S. 1998. New chemical descriptors relevant for the design of biologically active peptides. A multivariate characterization of 87 amino acids. Journal of Medicinal Chemistry 41: 2481-91.

SCHWEDE T, KOPP J, GUEX N and PEITSCH MC. 2003. SWISS-MODEL: an automated protein homology-modeling server. Nucleic Acids Research 31: 3381-85.

SKEHEL JJ, WILEY DC. 2000. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annual Reviews of Biochemistry 69: 531-569.

SNEATH PH. 1966. Relations between chemical structure and biological activity in peptides. Journal of Theoretical Biology 12: 157-195. 

STREET AG, MAYO SL. 1999. Intrinsic beta-sheet propensities result from van der Waals interactions between side chains and the local backbone. Proceedings of the National Academy of Science USA 96: 9074-76.

TEMOLTZIN-PALACIOS F, THOMAS DB. 1994. Modulation of' Immunodominant Sites in Influenza Hemagglutinin Compromise Antigenic Variation and Select Receptor-binding Variant Viruses. Journal of Experimental Medicine 179: 1719-24.

VARGHESE JN, COLMAN PM. 1991. Threedimensional structure of the neuraminidase of influenza virus A/TOKYO/3/67 at 2.2 Angstroms resolution. Journal of Molecular Biology 221: 473-486.

WILSON IA, COX NJ. 1990. Structural basis of immune recognition of influenza virus hemagglutinin. Annual Reviews of Immunology 8: 737-771.